SAR-445136 is a Gene-Modified Cell Therapy owned by Sangamo Therapeutics, and is involved in 2 clinical trials, which are ongoing.
SAR-445136 is designed to directly regulate sickle cell anemia related genes. BCL11-A modified hematopoietic stem progenitor cells act by direct regulation of disease-related genes and ZFNs to disrupt or correct therapeutically relevant genes. ZFP TFs regulate the cellular copy of the gene and mimic the cell’s natural method of gene regulation turning on or off all of the natural forms of the gene product. The therapeitic candidate allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.
The revenue for SAR-445136 is expected to reach a total of $319m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the SAR-445136 NPV Report.
SAR-445136 is under development for the treatment of hemoglobinopathies including sickle cell anemia. The therapeutic candidate consists of autologous CD34 hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2 and is administered as an intravenous infusion. It is developed based on Zinc Finger Proteins (ZFPs) technology.
Sangamo Therapeutics Overview
Sangamo Therapeutics (Sangamo), formerly Sangamo BioSciences, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Fabry disease, Huntington’s disease, Alzheimer’s disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.
The company reported revenues of (US Dollars) US$110.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 6.3% over FY2020. The operating loss of the company was US$183.3 million in FY2021, compared to an operating loss of US$129.6 million in FY2020. The net loss of the company was US$178.3 million in FY2021, compared to a net loss of US$121 million in FY2020.
The company reported revenues of US$29.4 million for the second quarter ended June 2022, an increase of 4.1% over the previous quarter.
Quick View – SAR-445136
|Highest Development Stage
#Revenue #SAR445136 #expected #CAGR